Form 4: Vyne Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations

Vyne Therapeutics' Chief Scientific Officer, Iain Stuart, sold 4,857 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Iain Stuart, the Chief Scientific Officer of Vyne Therapeutics, sold 4,857 shares of common stock on December 31, 2024.
• The sale was executed at a price of $3.35 per share.
• This transaction was to cover tax withholding requirements associated with the vesting of restricted stock units.
• Following the transaction, Iain Stuart directly owns 128,637 shares of Vyne Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales by executives.
• The number of shares sold and the price are specific to this individual and company, but the underlying reason for the sale is typical.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a routine transaction.

Key Dates

Keywords

Vyne Therapeutics, insider trading, stock sale, Form 4, Iain Stuart, restricted stock units, tax withholding